The risk of adverse drug effects and harm may increase in correlation with complex medication regimens, often present in heart failure with preserved ejection fraction. Researchers here attempted to describe this complexity by ascertaining the prevalence of polypharmacy, potentially inappropriate medications, and therapeutic competition (where a medication for one condition worsens another condition) in one of the few dedicated heart failure with preserved ejection fraction programs in the United States. In this chart review, they assessed 231 patients with heart failure with preserved ejection fraction and identified polypharmacy in 74%. Potentially inappropriate medications were prevalent in 100%. Presence of competing conditions was noted in 81% of patients, of whom 49% took a medication that created therapeutic competition. The high prevalence of polypharmacy and potentially inappropriate medications and frequent presence of therapeutic competition support the urgent necessity to develop patient-centered approaches to reduce the negative effects of complex medication regimens endemic to adults with heart failure with preserved ejection fraction.
Read the full article on American Journal of Medicine.